Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Non-Current Debt (2020 - 2023)

Historic Non-Current Debt for C4 Therapeutics (CCCC) over the last 4 years, with Q1 2023 value amounting to $8.6 million.

  • C4 Therapeutics' Non-Current Debt fell 1543.06% to $8.6 million in Q1 2023 from the same period last year, while for Mar 2023 it was $8.6 million, marking a year-over-year decrease of 1543.06%. This contributed to the annual value of $9.2 million for FY2022, which is 1460.81% down from last year.
  • C4 Therapeutics' Non-Current Debt amounted to $8.6 million in Q1 2023, which was down 1543.06% from $9.2 million recorded in Q4 2022.
  • C4 Therapeutics' 5-year Non-Current Debt high stood at $10.8 million for Q4 2021, and its period low was $8.6 million during Q1 2023.
  • In the last 4 years, C4 Therapeutics' Non-Current Debt had a median value of $10.2 million in 2022 and averaged $9.9 million.
  • Its Non-Current Debt has fluctuated over the past 5 years, first soared by 719.85% in 2021, then crashed by 1543.06% in 2023.
  • C4 Therapeutics' Non-Current Debt (Quarter) stood at $10.1 million in 2020, then increased by 7.12% to $10.8 million in 2021, then fell by 14.61% to $9.2 million in 2022, then decreased by 6.24% to $8.6 million in 2023.
  • Its Non-Current Debt was $8.6 million in Q1 2023, compared to $9.2 million in Q4 2022 and $9.1 million in Q3 2022.